• Recent report forecasts REE space to see 4% CAGR through 2027
• Demand for magnets projected to increase demand for rare earth elements
• Energy Fuels is the only U.S. company producing an REE product this far down the REE supply chain

A recent Mordor Intelligence article is reporting that the global rare earth elements (“REE”) market has reached an estimated 161,354.65 tons this year, with an expected compound annual growth rate (“CAGR”) of more than 4% between now and 2027 (https://ibn.fm/6UppN). That growth could prove beneficial to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), a leading U.S.-based uranium mining company that is also moving faster than any other company to re-establish a domestic REE supply chain. According to Mordor, factors driving the growth of the market include high demand from emerging economies and dependency of “green technology” on rare earth elements. “Rare earth elements usually have high electrical conductivity, and they naturally occur together in minerals,” the report continued. “Rare earth elements are the strongest magnets available today. The rare earth elements market is segmented by elements, applications and geography.” Looking closer at the demand for magnets, the report observed that magnets “stand to be one of the largest applications for rare earth elements “because they are used extensively in a wide array of industries, including electronics, automotive, power generation, medical, etc. “Magnets are used in computer hard drives, microwave power tubes, anti-lock brakes, automotive parts, disk drive motors, frictionless bearings, power generation, magnetic refrigeration, microphones and speakers, communication systems and MRI,” the report stated. “Industries, such as automotive, electronics and healthcare, have been witnessing innovation and development, driving the demand for magnets in such industries.” According to Mordor, last year approximately 85% of automakers were using neodymium-incorporated permanent magnet motors, and there are projections that automotive demand for rare earths will rise by 25% this year alone. In addition, “magnets are used in medical equipment, such as MRI machines, pacemakers, sleep apnea machines and insulin pumps,” the report noted. “Hence, all such trends are expected to noticeably drive the demand for magnets, which is further projected to increase the demand for rare earth elements in the coming years.” This bodes well for Energy Fuels. While maintaining its focus on being the largest U.S. producer of uranium, the company is also focused on responsibly producing the raw materials needed for the clean-energy revolution and, in 2021, began recovering REEs (https://ibn.fm/mHDnf). The effort is complementary, as the highest-value REE-bearing minerals also contain uranium and other naturally radioactive elements that need to be managed or recovered. UUUU’s White Mesa Mill in Utah is the only existing facility in North America with the licenses and capabilities to process monazite, the highest value REE mineral in the world. Last year, Energy Fuels began commercial production of an intermediate REE product, called “mixed rare earth carbonate” that is ready for REE separation without further processing, making it the only U.S. company producing an REE product this far down the REE supply chain. The company plans to fully integrate REE production in the next two to three years. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• The company reported growth across multiple areas in March 2022, including number of customers and subscriptions, spend per customer and revenue per subscriber
• The Friendable 360 artist offering provides independent artists with multiple production, distribution, and marketing opportunities, as well as several ways to earn revenue
• The new corporate presentation details the upcoming NFT and virtual offering for artists to digitize their music

Friendable (OTC: FDBL), a mobile technology and marketing company offering independent music artists control over their music through a 360 artist offering, has announced the release of a new corporate presentation that clearly outlines the company’s 2022 strategy (https://ibn.fm/30Usp). The company also released key metrics highlighting its overall growth for March 2022 over February 2022, showing increased traction, revenue, and user retention. The key metrics reported for March 2022 over February 2022 by the company include:

• New Customers – +55.6%
• New Subscribers – +38%
• Spend per Customer – +5.2%
• Revenue per Subscriber – +4.2%
• Subscriber Lifetime Value – +23.5%
• Subscriber Churn/Cancelation Rate – -15.6%

Robert A. Rositano, Jr., CEO of Friendable, reflected on the recent key metric report and overall company growth, stating that one of the most rewarding parts of building the brand and positioning the company in the independent artist marketplace was the feedback received from artists on how the Friendable offering can better support their journey to success. “From social media to revenue and user increases, as well as steady growth in key categories, it tells us everything we need to know about the path we are on as a Company, platform, team, and community of fledging artists, fans and investors all seeking to facilitate the launch and discovery of artists worldwide as we build a brand that stands alongside each one,” Rositano Jr. added. The new corporate presentation points out the overall market share in the industry – citing statistics including the 43.1% independent artist direct market share (MIDiA Research) and the projected 2024 revenue of independent artists, writers, and performers in the US being projected to reach $23.1 billion (Statista) (https://ibn.fm/dHdlU). The problems artists face in the industry include label control and expensive fees – both of which are eliminated through Friendable’s 360 artist offering including Fan Pass Live, Artist Republik, and FeaturedX. Friendable will be expanding its virtual and technological integration by incorporating non-fungible tokens (“NFTs”) to change how artists earn and distribute their music. The NFT offering will allow artists to earn additional revenue by offering the resources necessary to turn their music into NFTs that can be sold or traded to fans, collectors, and music enthusiasts. As technology continues to integrate with virtual capability, Friendable is committed to remaining at the forefront of new technology in the music industry. The Friendable 360 artist offering provides independent artists with the following production, distribution, and marketing opportunities:

• Ticketed Events
• Live Shows
• Custom Merchandise
• Logo Design
• Fan Tips
• Fan Interaction
• Artist Management
• Revenue Generation
• Promotion
• So much more!

Friendable also offers artists several revenue generating opportunities, including a portion of fan subscriptions, ticket sales, tips, and more. One hundred percent of the royalties for the artist’s music are paid to the artist, with no intermediary. Artists are also given the best rates in the industry to access the 360 artist offering – $5.00/single; $11.00/album; $14.99/subscription. There is no annual fee required for the services, and Friendable offers the highest level of promotion in the industry – social links, playlisting, PR, radio promo, distribution, websites, and more. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

Cannabis enthusiasts, traders, cultivators and allied industries are invited to attend the O’Cannabis Expo & Awards from June 1-3, 2022 In Toronto, Canada. After the last year’s rescheduling, the O’Cannabis Conference is back this year for a physical 3-day event. The team is grateful to the exhibitors, sponsors, partners as well as pre-purchased ticket holders for their patience and trust. The event venue is the International Centre Hall #5, Toronto, Canada, a hub of business and consumer exhibitions in Canada. O’Cannabiz is a leading company engaged in organizing national high-profile events, to foster global connections between business houses and the trading community of the arts, broadcasting, media and technology niche. They bring in years of experience in organizing top-notch trade summit initiatives with governments worldwide and have the experience of working with sponsors at all levels of the Canadian government. The event venue is an expansive 50,000 sq. ft hall that will witness 3500+ attendees networking in 70+ high-intensity sessions, with 180+ eminent industry speakers sharing their insights on cannabis extraction, trading, laws and regulations, and compliance in Canada. They will present their views and share strategies that will pave way for the future of the cannabis business and trading. These thought leaders will also discuss a wide spectrum of topics ranging from cultivation, marketing, branding, retail, policy and regulations, finance, as well as the future of cannabis and how that impacts all sectors of the cannabis business. Distinguished companies and giant business houses are sponsors of the event and exhibitors will set up booths to display their line of products and services. The O’Canna Retail Expo & Summit, a subset of the O’Cannabis Conference, will witness some of the best retail experts who will discuss the best practices, customer service, merchandising, digital marketing, and essential business and technology needs in a 360-degree approach to retail. The event will also host an award show to facilitate the contribution of dignitaries and cannabis professionals for their contribution to the cannabis industry, hosted by Gerry Dee, Host of Family Feud Canada and star of the award-winning sitcom, Mr D. The 3-day event includes a VIP Business Conference, Psychedelic Summit and an O’Cannabiz Awards Dinner Gala among other high profile events. Attendees can network and connect with influential industry veterans and learn the latest industry trends in cannabis cultivation, extraction, retail and trading. For more details, please visit https://ocannabiz.com/.

• Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings, just expanded its treatment options to include SPRAVATO(R) nasal spray beginning April 1
• SPRAVATO received FDA approval back in 2019 and would be used in conjunction with an oral antidepressant
• Its introduction to KWC clinics underscores the company’s commitment to providing clinically-backed, accessible and affordable treatments to patients nationwide

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), through its wholly-owned subsidiary, Delic Labs, has remained committed to expanding its ability to research novel compounds and developing intellectual property (“IP”) for future commercialization of novel psychedelic compounds for medical use. So far, the company has explored MDMA, LSD, DMT, mescaline, 2C-B, and psilocybin mushrooms (https://ibn.fm/iIiQu). These efforts have offered more effective alternatives to individuals dealing with treatment-resistant depression, anxiety, or post-traumatic stress disorder (“PTSD”). As it currently stands, over 63% of Americans who have used prescription medications to treat depression, anxiety, or PTSD, have reported that while the medication helped, they still underwent residual feelings of their conditions. In addition, 83% of those who have experienced these conditions before have noted that they are open to exploring alternative treatments that are more effective than prescription medications. In what marked a significant move for the company, Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings and the largest ketamine therapy provider in the United States, announced the expansion of its treatment options to include SPRAVATO(R) nasal spray beginning April 1 (https://ibn.fm/0r6nf). SPRAVATO is the first FDA-approved ekestamine nasal spray for adults, made explicitly for treatment-resistant depression (“TRD”) along with the treatment of depressive symptoms in adults with major depressive disorder (“MDD”) with suicidal thoughts or actions. SPRAVATO received FDA approval for the treatment of TRD back in 2019 following an efficacy evaluation in three short-term (four-week) clinical tests, along with one longer-term maintenance-of-effect trial. The nasal spray would be used in conjunction with an oral antidepressant and would only be available through a restricted distribution system, under a Risk Evaluation and Mitigation Strategy (“REMS”) (https://ibn.fm/uyb48). While making the announcement, Kevin Nicholson, the Chief Executive Officer (“CEO”) of KWC and the Chief Operating Officer (“COO”) of Delic, noted that the introduction of SPRAVATO underscores KWC’s commitment to providing clinically-backed, accessible, and affordable treatments to patients nationwide. He further pointed out that the company’s dedication to offering the highest quality service available, coupled with its vast network of ketamine clinics, allows it to serve more patients than any other ketamine therapy provider. “Ketamine Wellness Centers strives to be our patients’ strongest advocate by providing effective and affordable mental health treatment, and SPRAVATO is the next step in maintaining that standard,” Mr. Nicholson noted. Patients who might be interested in this treatment option will undergo KWC’s thorough intake and screening process to ensure they are suitable candidates and would gain the most benefit from the treatment. In addition, KWC’s clinical protocols provide that SPRAVATO treatments are administered in precisely the proper care and patient safety settings. “Our team rigorously studied SPRAVATO’s clinical efficacy before offering the treatment to our wider patient community and expanding our care options,” noted Mr. Nicholson. “We are confident that adding this treatment to our mental wellness centers will greatly benefit our patients,” he added. Since Delic completed the acquisition of KWC in November 2021, it has been on an aggressive expansion plan, growing the number of locations to 13, up from 10, with plans to open more locations in the coming months. So far, these facilities serve communities across nine states in the United States and have provided over 70,000 treatments to clinically eligible patients, ranging from young adults to seniors (https://ibn.fm/2gL1y). The addition of SPRAVATO to KWC’s list of offerings guarantees more options for its patients. In addition, it allows both KWC and Delic to provide effective and affordable mental health treatment to patients across the country. For more information, visit the company’s website at www.DelicCorp.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• On March 31, GreenBox POS released the financial results for the three months (“Q4 FY 2021”) and full year (“FY2021”) ended December 31, 2021
• Company achieved record revenue in 2021 of $26.3 million, an increase of $17.8 million or 208.6% from $8.5 million in 2020
• The Q4 FY2021 results build on Q3 2021 figures in which the company reported year-over-year growth in both transaction volume and revenues
• The financial figures were accompanied by a corporate update and expected prospects for 2022.

On Thursday, March 31, at 4.30 PM Eastern, investors, stakeholders, and the general public heard about the progress that GreenBox POS (NASDAQ: GBOX), an emerging FinTech company leveraging blockchain technology to offer cutting-edge, customized payment solutions, made in the three months ended December 31, 2021 (“Q4 FY2021”) as well as throughout fiscal year 2021 (“FY2021”). GreenBox achieved record revenue in 2021 of $26.3 million, an increase of $17.8 million or 208.6% from $8.5 million in 2020. Processing volume for 2021 increased nearly tenfold to approximately $2.0 billion, from $202 million in 2020 (https://ibn.fm/zEGds). At the same time, GreenBox management hosted a conference call to discuss the financial results, offered a corporate update, and fielded questions from participants. A recording of the conference call was made available for 90 days on its website’s IR section. “Despite all GreenBox has accomplished in the last 18 months, we are still just in the early innings of our technology. We remain confident in our long-term strategy and are well positioned to capitalize on the opportunities at hand,” GreenBox CEO Fredi Nisan commented in a November 11, 2021 news release announcing the Q3 FY2021 results (https://ibn.fm/PZBgR). “2020 unquestionably proved our ability to develop and deploy cutting-edge technology. In 2021, we focused on executing on our strategy to build sustainable scale for our products, while adding new leadership team members that will drive our growth plan and establish GreenBox as a world-class brand,” said Fredi as part of the announcement of the preliminary results. “There’s a lot of pride around these 2021 results, no doubt. But, make no mistake, we remain laser-focused on molding the future of this company and our determination of becoming the global leader in the digital financial solutions marketplace,” Fredi concluded. In keeping up with the growth trajectory, GreenBox expects to process at least $4.9 billion in transactions in 2022. The company has also slated several strategic acquisitions for 2022, according to transcripts from the company’s December corporate call (https://ibn.fm/cSp1q). For more information, visit the company’s website at www.GreenBoxPOS.com. NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at https://ibn.fm/GBOX

• Over 31 million Americans have hearing loss but don’t utilize a hearing aid, primarily due to prohibitively high costs
• In the last 5 years, U.S. Presidents and Congress has demonstrated a strong commitment to making hearing aids affordable to all, including pressure on the FDA to complete changes now
• InnerScope has aggressively grown its business model through two key acquisitions and new sales channels that should lend to significant revenue growth as new regulations are put in place

More than 38 million Americans have some degree of hearing loss. Sadly, due mostly to prohibitively high costs, only about 20% of those people are able to improve their quality of life using hearing aids. The winds of change are blowing in for the 31 million Americans left behind, thanks to Congress prodding the U.S. Food and Drug Administration (“FDA”) to make changes and companies like InnerScope Hearing Technologies (OTC: INND) disrupting the market with new Direct-to-Consumer (“DTC”) technologies. In 2017, President Trump signed the Over-the-Counter Hearing Aid Act into law. The new law received strong bipartisan support to eliminate arcane regulations limiting availability to over-the-counter (“OTC”) hearing aids while supporting new competition in the markets to drive prices down to a level affordable by all. In July 2021, President Biden issued the Executive Order on Promoting Competition in the American Economy, which detailed his commitment to promoting OTC hearing aids for those in need. Now, it is time for the FDA to act with the comment period for key provisions in the FDA’s proposed rule for regulating OTC hearing aids ended on January 18, 2022. Congress is getting impatient with the FDA to finalize the rules to exclude any unnecessary restrictions that hinder access to OTC devices or limit their effectiveness for Americans with mild or moderate hearing loss. This point was made clear in a letter penned by Senators Chris Van Hollen (D-Md.), Elizabeth Warren (D-Mass.), and Chuck Grassley (R-Iowa) to Janet Woodcock, Acting Commissioner of the FDA, in February, which implored the agency to “finalize this rule without delay and in a manner that is consistent with congressional intent.” Changing regulations to support affordable hearing aids and competition is aligned perfectly with InnerScope expanding its business through a combination of key acquisitions and a network of major retailers and pharmacy chains. Headquartered in Roseville, California, InnerScope is a leading DTC manufacturer and distributor of FDA-registered hearing aids, hearing assistive devices, hearing health-related products, and Personal Sound Amplifier Products (“PSAPs”). Late in 2021, InnerScope moved aggressively to expand operations, buying iHear Medical and HearingAssist. The acquisition of iHear Medical brought a 40+ hearing technology patent portfolio, a research, and development team, and an R&D facility into the InnerScope family. Merging with HearingAssist was an instant revenue injection and scaling opportunity as an emerging industry powerhouse. A major hearing aid supplier to Walmart, HearingAssist generated $72 million in gross revenues in the three years before the InnerScope acquisition. These operations complement the overall InnerScope strategy to serve the millions of people that will benefit from new FDA rules. InnerScope has built out a comprehensive ecosystem, complete with an eCommerce site (www.iHearDirect.com) and a newly launched call center (www.HearingAssist.com, 1-800-700-4327), where its customers have free access to a team of highly-experienced industry talent, consisting of licensed hearing professionals, including doctors of audiology, top salespeople, and a team of hearing aid customer care representatives. The company further offers its hearing aids through partnerships with www.FSAstore.com, www.HSAstore.com, and www.WellDeservedHealth.com, online stores specializing in serving consumers enrolled in flexible spending accounts (“FSA”), health saving accounts (“HSA”), and employers’ health incentive programs. The relationship with Walmart took another positive turn with select InnerScope products making their debut in the retail giant’s online store in Canada (www.Walmart.ca). Initially, the site will feature INND’s TReO(TM) by iHEAR(R) 3-IN-1 PSAP, Hearing Assist TV Listener / Hearing Amplifier, Hearing Assist Earwax Removal Ear Spray, and Hearing Assist Dehumidifier for Hearing Aids. Hearing loss is prevalent in Canada, much like the U.S., affecting about 65% of Canadians over the age of 70. New research from Statistics Canada shows that more than half of Canadians between the ages of 40 and 79 have at least mild hearing loss, but 77% of them don’t realize it. Late in March, InnerScope announced that 9 of its products are now available on the eCommerce site of Rite Aid. The initial launch included HearingAssist’s hearing aid care and assorted hearing aid batteries, earwax removal ear spray, and a Wireless Neckband TV Listener Hearing Amplifier. Elsewhere, in recent months, InnerScope updated in-store product displays in 757 Walmart locations throughout Colorado, Tennessee, Texas, Arizona, and North Carolina; and launched 14 in-store Hearing Screening Kiosks with Hy-Vee, Giant Eagle, Food City, and Hartig Drug as part of a larger package where over 65 kiosks are already committed to retailers. Investors will be looking forward to upcoming quarterly reports to see the effect of the acquisitions, new call center, kiosks, and expanded sales channels on the top and bottom lines.  The company recently released its 2021 annual report, which showed revenues increased from $529,192 to $695,053 for fiscal 2021. Gross profits rose from $113,371 in fiscal 2020 to $490,266. With all the recent developments, InnerScope CEO and President Matthew Moore commented, “[We] have an exciting roadmap for 2022 clearly defined ahead and after the Over-the-Counter Hearing Aid Law is enacted. We continue to add new retailers to our ever-growing distribution list, including, as previously announced, Rite Aid Pharmacy. In addition, our R&D team is working to bring new proprietary patented hearing aid products to market later this year.” For more information, visit the company’s website at www.INND.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• TripAdvisor’s annual roundup of top destinations shows travelers returning to normalcy
• SHRG’s Hapi Travel Destinations focuses on offering discounted destinations with a maximized experience
• Company differentiates itself by offering unfettered access to tremendous savings, exclusive benefits on a level never before seen

Despite the global pandemic still impacting life in many ways, most indicators show that travel is picking back up. This is good news for Sharing Services Global (OTCQB: SHRG) and its new direct-selling travel division, which offers exclusive benefits and first-class discount travel opportunities. “The popular bookings website [TripAdvisor] recently published its annual roundup of top destinations, and there’s perhaps no greater sign of return to normalcy than the fact that people are once again flocking to pack beaches up and down the European coast,” reported a recent “Fast Company” article (https://ibn.fm/NUnVE). “Five of the top-10 trending destinations worldwide, which saw the largest year-over-year rise in interest on the platform, belong to the Mediterranean shoreline, including the Spanish island of Majorca, which took the top spot, as well as Rhodes and Santorini in the Aegean Sea, and Dubrovnik, Croatia, often called the ‘pearl of the Adriatic,’ and one of many countries that beckoned to digital nomads during the thick of the pandemic.” The article went on to note that within the United States, 2022’s most popular destinations included Las Vegas, which took the top spot, and New York City, New Orleans, and Nashville. Regardless of where travelers are heading, SHRG’s Hapi Travel Destinations is committed to helping them get there (https://ibn.fm/iMTNL). The company is focused on offering discounted destinations with a maximized experience and works to offer “hapi” experiences that inspire purpose and unity. The company believes that the best traveling involves sharing the joy of a global community filled with customs, cultures and experiences that enhance and enrich the lives of travelers. With its unique vision that “everyone deserves a hapi life with a bucket list of travel,” the company is committed to bringing its members world-class adventures at affordable prices. SHRG’s Hapi Travel Destinations is a travel company whose time has come. As travelers head back out in the world after a long break, they are looking for new experiences. Hapi Travel is dedicated to providing exactly that as it differentiates itself by offering unfettered access to tremendous savings and exclusive benefits to its members on a level that the industry has not seen before. Sharing Services Global Corporation is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit the company’s websites at www.SHRGInc.com, www.TheHappyCo.com, and www.HapiTravel.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Novel brain cancer drug developer CNS Pharmaceuticals is developing a proprietary pharmaceutical candidate called Berubicin for the treatment of glioblastoma multiforme (“GBM”)
• CNS has received Fast Track designation for Berubicin, which will allow the company more frequent communications with the FDA
• CNS has initiated a global potentially pivotal clinical trial to evaluate Berubicin in treating GBM and began dosing patients at sites scattered across several states last year, with numerous additional sites preparing to enroll patients in the coming months
• CNS is now reporting approval from regulatory authorities in Switzerland and France to proceed with recruiting patients there
• The study will evaluate more than 200 patients worldwide who have had a recurrence of tumor progression following standard first line therapy
• The company expects interim results from the study in 2023 after 30 to 50 percent of the total expected patients have reached the six-month point, with a primary completion date in October 2024 and ultimate resolution in February 2025

Biopharmaceutical cancer drug developer CNS Pharmaceuticals (NASDAQ: CNSP) is reporting new advances in its rollout of a global clinical trial the company describes as “potentially pivotal” in producing a treatment for an aggressive brain cancer. CNS Pharmaceuticals began recruiting and dosing patients with novel anthracycline drug candidate Berubicin in 21-day cycles last year at locations throughout the United States, and the company is continuing to prepare for recruitment at numerous other U.S. location as well as in Europe (https://ibn.fm/2azMa). Berubicin is a drug candidate for the treatment of glioblastoma (“GBM”), a brain cancer that is nearly 100 percent fatal just over a year after it’s diagnosed, on average. During the century since GBM was first identified in patients, only four drugs and one device have been approved by the U.S. Food and Drug Administration (“FDA”) to treat it, and none of the treatments have been able to significantly extend patients’ lives beyond “a few extra months,” according to the National Brain Tumor Society (https://ibn.fm/PdGXe). On April 6, CNS announced that France’s regulatory agencies have granted the company authority to pursue patient recruitment in the country, with approval for the Berubicin study coming from the National Agency for the Safety of Medicine and Health Products (“ANSM”) Competent Authority and from the People Protection Ethics Committee (“EC”) SUD-EST III (CPP Sud-Est III) (https://ibn.fm/BBy5g). France’s approval comes on the heels of similar authorization in Switzerland, where Swissmedic, the Swiss agency for therapeutic products, joined swissethics, the umbrella organization of the cantonal Ethics Committees (“ECs”), in green-lighting the clinical studies (https://ibn.fm/WfRwB). “We have said time and again that our number one priority is the advancement of this potentially pivotal study. This is evidenced by our continuous dedication to driving enrollment and bringing global clinical sites on line,” CNS CEO John Climaco stated in the most recent news release. More than 200 adult patients will participate in the “adaptive, multicenter, open-label, randomized and controlled study.” The company also hopes to establish sites in Spain and Italy, and plans to report an interim analysis of patients when 30 to 50 percent of them have reached the six-month point on study. The excitement behind Berubicin stems from its apparent ability to cross the blood-brain barrier — something unheard of in cancer-fighting anthracyclines. And an initial evaluation of Berubicin’s safety by another company 16 years ago resulted in one patient who emerged cancer-free — surviving well beyond the expected amount of time for people with GBM, and still alive and cancer free as of November 2021. Among the other 26 patients included in that initial safety test, 12 achieved some improvement or stabilization of their condition for a period of time, according to the company (https://ibn.fm/aLYwR). “The data Berubicin has shown to-date demonstrates encouraging promise in treatment of GBM. Patients and families are desperate for a viable treatment option that provides benefit and I look forward to further exploring Berubicin’s potential,” CNS’s national coordinating investigator partner in Switzerland, professor Michael Weller, MD, of the University Hospital Zurich, stated. CNS expects a primary completion date of October 2024 for the study, with final completion by February 2025 (https://ibn.fm/mhJ2b). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Lexaria Bioscience, the global innovator behind DehydraTECH drug delivery technology, has continuously focused on research into its patented technology
• The company has conducted both in vitro testing and in vivo animal and human testing to evaluate the ability of DehydraTECH to improve the delivery of various APIs (active pharmaceutical ingredients)
• Lexaria has multiple other studies lined up aimed at building sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation

As it moves toward national and international implementation and commercialization of its patented DehydraTECH(TM) drug delivery technology, Lexaria Bioscience (NASDAQ: LEXX) is aware of the need to continuously advance its understanding of the technology’s capabilities and potential applications. This informs the company’s long-held commitment to its applied research and development (“R&D”) programs, which are exclusively designed to “reduce future risks of both commercial and regulatory failure by identifying weaknesses as early as possible; and to enhance the likelihood of future commercial and regulatory success by thoroughly understanding strengths and weaknesses, also as early as possible” (https://ibn.fm/RPxts). Lexaria’s DehydraTECH technology combines a lipophilic active pharmaceutical ingredient (“API”) with a carrier particle, then it is dehydrated and finally rendered as a liquid or powder. Through the years, Lexaria has proven that DehydraTECH results in additional improvements, including speed of onset, increased brain absorption, increased bioavailability, and reduced drug administration costs, thanks to extensive research the company has continuously undertaken since 2015. So far, the research journey has involved a series of controlled and well-designed in vitro pre-clinical testing and in vivo animal and human clinical studies, as well as all-encompassing molecular characterization investigations, which have been completed on APIs such as antiviral drugs, cannabinoids, nicotine and nicotine analogs, PDE5 inhibitors and non-steroidal anti-inflammatory drugs (“NSAIDs”). The company’s in vitro pre-clinical test, an absorption study, was performed to investigate unidirectional cannabidiol (“CBD”) permeability using a human epi-intestinal tissue model with multiple formulations in the presence of simulated intestinal fluid. According to Lexaria, the study evidenced a 325% and 499%, on average, in intestinal tissue permeability compared to two control groups. Lexaria has also undertaken extensive clinical research starting in 2016. Multiple independent, well-designed, and controlled human studies conducted between 2016 and 2017, for example, corroborated the results from the in vitro studies. Since then, the company has undertaken numerous other studies evaluating the performance of various APIs processed using the DehydraTECH technology. For instance, Lexaria has investigated DehydraTECH-CBD as a potential treatment for hypertension and heart disease in multiple human studies, DehydraTECH-processed nicotine (animal study), and antivirals. “Performance of total bioabsorption (directly and indirectly through surrogate biomarkers), blood-brain-barrier delivery characteristics, rapidity of onset, consumer appeal, metabolite production (an indication of first-pass liver bypass), and quality of effectiveness have all been quantified,” Lexaria’s website says of the investigation parameters (https://ibn.fm/Ni2J1). Still, Lexaria is unrelenting in its pursuit of comprehensive datasets that would answer many questions the company expects to face from potential commercial partners or regulators and is, in fact, expanding its research. Last month, Lexaria kicked off an animal study to evaluate DehydraTECH-CBD as a potential treatment to inhibit seizure activity (https://ibn.fm/sX6tE), the first in a series of additional planned animal studies tentatively set to commence this year (https://ibn.fm/4as8P). Others include:

• HOR-A22-1: an animal study to evaluate DehydraTECH’s ability to improve the delivery characteristics of estrogen
• DEM-A22-1: an efficacy study to investigate DehydraTECH-CBD with and without nicotine for the potential treatment of dementia
• RHEUM-A22-1: an efficacy study to evaluate the ability of DehydraTECH-CBD to potentially impact the treatment of rheumatoid disease
• DIAB-A22-1: an efficacy study to investigate DehydraTECH-CBD’s ability to potentially affect the treatment of diabetes

“DehydraTECH is not an EVOLUTION of existing technology – it is a REVOLUTIONARY new drug delivery platform. Expecting entire industries to change overnight to adopt a revolutionary process is not realistic: it takes time, evidence, and a lot of positive results to overcome industry inertia. We have long been hopeful that, before the end of 2022, we will have built sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation,” Lexaria CEO Chris Bunka wrote in a recent letter to shareholders. And with the planned and ongoing human and animal studies, Lexaria hopes to achieve precisely this. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• There is an urgent need for large-scale biosynthetic processing that preserves the purity and consistency of cannabinoids
• Acquired by InMed in October 2021, Bay Medica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector
• InMed has two cannabinol formulations currently in development for ocular and dermatological diseases – INM-088 (ocular for glaucoma) and INM-755 (dermatological cream for epidermolysis bullosa)

The global cannabis market increased exponentially after the pandemic hit, and is anticipated to continue its upward trend over the next few years. The market was valued at $20.47 billion in 2020, reporting a growth rate of 50.92% that year. The sector reached $28.66 billion in 2021 and is anticipated to hit $197.74 billion in 2028, expanding at a CAGR of 32.04% (https://ibn.fm/2o10w). The market growth is paired with an increased demand for rare cannabinoids, with research showing that the biosynthesis of rare cannabinoids is projected to reach $25 billion in 2025 and up to $40 billion by 2040 (https://ibn.fm/jBXUs). The problem faced by companies looking to work with rare cannabinoids on an industrial scale is the lack of efficient biosynthetic production methods that can ensure purity and consistency at high levels of production. Many companies find small-scale processing efficient for maintaining purity and consistency, but InMed Pharmaceuticals (NASDAQ: INM), which sees the potential of rare cannabinoids, is looking to scale up their production to commercial levels, and advanced biosynthetic production methods are necessary to ensure purity and consistency at such levels. InMed is a clinical-stage company that is currently developing a pipeline of cannabinoid-based pharmaceutical drug candidates to treat several diseases with high, unmet medical needs. The company’s focus is on rare cannabinoids, many of which have variants that are not yet available in commercial-size quantities, such as cannabidivarin – CBDV and tetrahydrocannabivarin – THCV. The acquisition of Bay Medica in October 2021 has provided an advantage for InMed in the rare cannabinoid biosynthesis industry. Bay Medica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector and now operates as a subsidiary of InMed. Bay Medica is comprised of a team of key scientists and professionals from large-scale producers, which gives InMed the unique opportunity to use the technology to scale up the rare cannabinoid synthesis production. In a January news release, Shane Johnson, SVP and General Manager of Bay Medica, said the company was delivering on its objective to launch additional rare cannabinoids in early 2022 in response to inbound demand. “By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large-scale supplier of high-quality rare cannabinoids in these sectors,” Johnson explained. Evidence suggests that rare cannabinoids may produce exceptional therapeutic value. One of the rare cannabinoids that InMed has been working with is cannabinol (“CBN”). CBN is the active pharmaceutical ingredient (“API”) in two lead programs being pursued by the company for ocular and dermatological diseases. The company’s most advanced compound currently pursued is INM-755, a CBN topical cream under clinical development for treating epidermolysis bullosa (“EB”), a severe genetic skin disorder. InMed is also developing INM-088, an ocular CBN formulation researched for glaucoma treatment. INM-755 commenced a Phase 2 EB study across 13 sites in eight European countries in 2021. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM